Visseren FLJ - Search Results

1

Identifying treatment response to antihypertensives in patients with obesity-related hypertension.

Schrover IM, Dorresteijn JAN, Smits JE, Danser AHJ, Visseren FLJ, Spiering W. Schrover IM, et al. Among authors: visseren flj. Clin Hypertens. 2017 Oct 24;23:20. doi: 10.1186/s40885-017-0077-x. eCollection 2017. Clin Hypertens. 2017. PMID: 29085669 Free PMC article.

2

[Sensory disturbances caused by multivitamin preparations].

Spiering W, Visseren FL. Spiering W, et al. Ned Tijdschr Geneeskd. 2006 Feb 4;150(5):277; author reply 277. Ned Tijdschr Geneeskd. 2006. PMID: 16494000 Dutch. No abstract available.

3

[Infection-induced vascular disease: little evidence according to the Koch's postulates].

Visseren FL, Spiering W, Hoepelman IM. Visseren FL, et al. Ned Tijdschr Geneeskd. 2007 Dec 29;151(52):2883-7. Ned Tijdschr Geneeskd. 2007. PMID: 18257433 Review. Dutch.

4

Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.

Vlek AL, van der Graaf Y, Spiering W, Visseren FL; SMART study group. Vlek AL, et al. J Hum Hypertens. 2008 May;22(5):358-65. doi: 10.1038/jhh.2008.5. Epub 2008 Feb 14. J Hum Hypertens. 2008. PMID: 18273039

5

Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease.

Vlek AL, van der Graaf Y, Spiering W, Algra A, Visseren FL; SMART study group. Vlek AL, et al. J Intern Med. 2008 Oct;264(4):351-60. doi: 10.1111/j.1365-2796.2008.01970.x. Epub 2008 Jun 3. J Intern Med. 2008. PMID: 18522685 Free article.

6

Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease.

Wassink AM, Van Der Graaf Y, Soedamah-Muthu SS, Spiering W, Visseren FLj; Smart Study Group. Wassink AM, et al. Among authors: visseren flj. Diab Vasc Dis Res. 2008 Jun;5(2):114-22. doi: 10.3132/dvdr.2008.019. Diab Vasc Dis Res. 2008. PMID: 18537099 Free article.

7

Blood pressure, cerebral blood flow, and brain volumes. The SMART-MR study.

Muller M, van der Graaf Y, Visseren FL, Vlek AL, Mali WP, Geerlings MI; SMART Study Group. Muller M, et al. J Hypertens. 2010 Jul;28(7):1498-505. doi: 10.1097/HJH.0b013e32833951ef. J Hypertens. 2010. PMID: 20453669

8

Vascular and metabolic effects of 12 days intensive walking to Santiago de Compostela.

Bemelmans RH, Coll B, Faber DR, Westerink J, Blommaert PP, Spiering W, Visseren FL. Bemelmans RH, et al. Atherosclerosis. 2010 Oct;212(2):621-7. doi: 10.1016/j.atherosclerosis.2010.06.012. Epub 2010 Jun 11. Atherosclerosis. 2010. PMID: 20598693

9

[Obesity-related hypertension].

Dorresteijn JA, Visseren FL, van den Meiracker AH, Spiering W. Dorresteijn JA, et al. Ned Tijdschr Geneeskd. 2011;154:A1945. Ned Tijdschr Geneeskd. 2011. PMID: 21418695 Review. Dutch.

10

Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.

Westerink J, van der Graaf Y, Faber DR, Spiering W, Visseren FL; SMART study group. Westerink J, et al. Eur J Prev Cardiol. 2012 Aug;19(4):864-73. doi: 10.1177/1741826711416045. Epub 2011 Jul 1. Eur J Prev Cardiol. 2012. PMID: 21724680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

505 results

Search Page

Filters